CTLA4 and neoplasm: ICB enhances the immune system’s ability to attack tumor cells by inhibiting immune checkpoint molecules, such as PD-1, PD-L1, and CTL-associated protein-4 (CTLA-4), and by reducing T-cell inhibition within the TME (168).